BRIEF—Almirall to use AI to speed up drug discovery

Spain's Almirall and Iktos, a company specializing in artificial intelligence for novel drug design, have agreed to collaborate to speed up the identification of promising drug candidates for an undisclosed Almirall drug discovery program.

Iktos’ AI technology works by automatically designing virtual novel molecules that have the desirable characteristics of a novel drug candidate.

Almirall chief scientific officer Bhushan Hardas said: “The health sector lags behind others in the digital world. Almirall wants to be at the forefront of innovation to develop holistic and transversal approaches.”

To find out more about Almirall's digital transformation from the company's chief digital officer, read here.